The Potential Prognostic Impact and Intercorrelations between CTLA-4, PD-1/PD-L1 and CD73/A2AR Immune Checkpoint Molecules in Colorectal Cancer

被引：0
|
作者：
Aboelnasr, L. [1 ,2 ]
Abdou, A. [3 ]
机构：
[1] Menoufia Univ Hosp, Menoufia, Egypt
[2] Imperial Coll London, London, England
[3] Menoufia Univ, Menoufia, Egypt
来源：
JOURNAL OF MOLECULAR DIAGNOSTICS | 2023年 / 25卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
ST150
引用
收藏
页码：S140 / S141
页数：2
相关论文
共 50 条
  • [41] PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
    Hartkopf, Andreas D.
    Taran, Florin-Andrei
    Wallwiener, Markus
    Walter, Christina B.
    Kraemer, Bernhard
    Grischke, Eva-Maria
    Brucker, Sara Y.
    BREAST CARE, 2016, 11 (06) : 385 - 390
  • [42] Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer
    Baraibar, Iosune
    Melero, Ignacio
    Ponz-Sarvise, Mariano
    Castanon, Eduardo
    DRUG SAFETY, 2019, 42 (02) : 281 - 294
  • [43] Immunohistochemistry of immune checkpoint markers PD-1 and PD-L1 in prostate cancer
    Sharma, Meenal
    Yang, Zhiming
    Miyamoto, Hiroshi
    MEDICINE, 2019, 98 (38)
  • [44] PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon, Tawee
    Gray, Jhanelle E.
    Antonia, Scott J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (03) : 305 - 312
  • [45] The Immune Microenvironment of HER2 Positive Breast Carcinomas; CTLA-4 Expression and the PD-1/PD-L1 Axis
    Rosen, Lauren
    Novo, Jorge
    Ubago, Julianne M.
    Pincus, Jennifer
    Blanco, Luis
    Siziopikou, K. P.
    MODERN PATHOLOGY, 2018, 31 : 100 - 100
  • [46] The Immune Microenvironment of HER2 Positive Breast Carcinomas; CTLA-4 Expression and the PD-1/PD-L1 Axis
    Rosen, Lauren
    Novo, Jorge
    Ubago, Julianne M.
    Pincus, Jennifer
    Blanco, Luis
    Siziopikou, K. P.
    LABORATORY INVESTIGATION, 2018, 98 : 100 - 100
  • [47] Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    Wu, Yingcheng
    Ju, Qianqian
    Jia, Keren
    Yu, Jingyan
    Shi, Hui
    Wu, Huiqun
    Jiang, Maorong
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 45 - 51
  • [48] The impact of PD-L1 as a biomarker of cancer responses to combo anti-PD-1/CTLA-4
    Parvini, Sasan
    Majidpoor, Jamal
    Mortezaee, Keywan
    PATHOLOGY RESEARCH AND PRACTICE, 2023, 247
  • [49] PD-L1/PD-1 and CTLA-4 Expression in Equine Penile Squamous Cell Carcinomas
    Porcellato, Ilaria
    Mecocci, Samanta
    Brachelente, Chiara
    Cappelli, Katia
    Armando, Federico
    Tognoloni, Alessia
    Chiaradia, Elisabetta
    Stefanetti, Valentina
    Mechelli, Luca
    Pepe, Marco
    Gialletti, Rodolfo
    Passeri, Benedetta
    Ghelardi, Alessandro
    Razzuoli, Elisabetta
    ANIMALS, 2021, 11 (07):
  • [50] Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Xu, Li
    Yan, Xin
    Ding, Weiyue
    FRONTIERS IN ONCOLOGY, 2022, 12
12345